# Sonidegib

Source: https://onco.cc/drugs/sonidegib/  
OnCo record `sonidegib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sonidegib (Odomzo) is the second hedgehog inhibitor for locally advanced basal cell carcinoma, similar in effect and side effects to vismodegib.

## Summary

Sonidegib is an oral smoothened (SMO) antagonist that blocks hedgehog signalling, the pathway driven by PTCH1 or SMO mutations in nearly all basal cell carcinomas. It has a long half-life and high tissue distribution. In the BOLT trial (2015), 56% of patients with locally advanced BCC responded to the 200 mg dose, with responses that remained durable at 42 months of follow-up. It was approved in the US and EU in 2015 for locally advanced BCC that has recurred after surgery or radiation or in patients who are not candidates for those treatments, but not for metastatic disease. Its adverse effects are those of the class: muscle spasms, taste disturbance, hair loss and raised creatine kinase, which often lead to dose interruption. For a newcomer, sonidegib is the second hedgehog pill for advanced basal cell carcinoma and behaves much like vismodegib.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-08
- Tags: gap-fill
- Brand: Odomzo
- Modality: Small-molecule smoothened inhibitor
- Mechanism: SMO antagonist blocking hedgehog signalling; long half-life and high tissue distribution.
- Approvals: US 2015: Locally advanced BCC recurrent after surgery or radiation, or not candidates; EU 2015: Same

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Sonidegib
- Label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=sonidegib

## Connected records

- cancers: [Basal cell carcinoma](https://onco.cc/cancers/basal-cell-carcinoma/), [Locally advanced and metastatic basal cell carcinoma](https://onco.cc/cancers/locally-advanced-bcc/), [SHH-activated medulloblastoma](https://onco.cc/cancers/medulloblastoma-shh/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- technologies: [Hedgehog pathway inhibitors](https://onco.cc/technologies/hedgehog-inhibitors/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [PTCH1 (Patched 1)](https://onco.cc/targets/ptch1/), [Smoothened (hedgehog pathway)](https://onco.cc/targets/smoothened/)
- companies: [Novartis](https://onco.cc/companies/novartis/), [Sun Pharmaceutical Industries](https://onco.cc/companies/sun-pharma/)
- terms: [Medulloblastoma molecular groups (WNT, SHH, group 3, group 4)](https://onco.cc/terms/medulloblastoma-molecular-groups/), [Why people stop taking hedgehog inhibitors](https://onco.cc/terms/hedgehog-inhibitor-tolerability/)
- key papers: [BOLT: two doses of sonidegib in locally advanced or metastatic basal cell carcinoma](https://onco.cc/key-papers/paper-bolt-sonidegib-migden-lancet-oncol-2015/)
- pathways: [Basal cell carcinoma (KEGG map)](https://onco.cc/pathways/basal-cell-carcinoma-signalling/), [Fibroblast activation, desmoplasia & matrix stiffness](https://onco.cc/pathways/caf-activation-desmoplasia/)
- drugs: [Patidegib](https://onco.cc/drugs/patidegib/)
- trials: [BOLT](https://onco.cc/trials/bolt/)

---
JSON: https://onco.cc/api/v1/entities/sonidegib.json